FDA adcomm votes again to remove controversial preterm birth drug from market - Endpoints News

The Medicines Patent Pool on Thursday unveiled a new voluntary license agreement with Novartis to increase access to its patented second-line chronic myeloid leukemia drug Tasigna (nilotinib) in certain low-income countries.

The drug, which is on the WHO Essential Medicines List, will now be manufactured by selected generic manufacturers and offered in seven middle-income countries – Egypt, Guatemala, Indonesia, Morocco, Pakistan , the Philippines and Tunisia – where product patents are pending or in effect.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join over 151,600 biopharma professionals reading Endpoints daily – and it’s free.

Leave a Reply

Your email address will not be published.